Prognostic value of soluble ST2, high-sensitivity cardiac troponin, and NT-proBNP in type 2 diabetes: a 15-year retrospective study.
Cardiovascular risk
Natriuretic peptides
Soluble ST2
Troponin
Type 2 diabetes
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
10 09 2022
10 09 2022
Historique:
received:
03
08
2022
accepted:
02
09
2022
entrez:
10
9
2022
pubmed:
11
9
2022
medline:
14
9
2022
Statut:
epublish
Résumé
Patients with type 2 diabetes (T2DM) present an increased risk of cardiovascular (CV) disease and excess CV-related mortality. Beyond the established role of brain natriuretic peptide (BNP) and cardiac troponins (cTn), other non-cardiac-specific biomarkers are emerging as predictors of CV outcomes in T2DM. Serum levels of soluble suppression of tumorigenesis 2 (sST2), high-sensitivity (hs)-cTnI, and N-terminal (NT)-proBNP were assessed in 568 patients with T2DM and 115 healthy controls (CTR). Their association with all-cause mortality and the development of diabetic complications was tested in T2DM patients over a median follow-up of 16.8 years using Cox models and logistic regressions. sST2 followed an increasing trend from CTR to uncomplicated T2DM patients (T2DM-NC) to patients with at least one complication (T2DM-C), while hs-cTnI was significantly higher in T2DM-C compared to CTR but not to T2DM-NC. A graded association was found between sST2 (HR 2.76 [95% CI 1.20-6.33] for ≥ 32.0 ng/mL and 2.00 [1.02-3.94] for 16.5-32.0 ng/mL compared to < 16.5 ng/mL, C-statistic = 0.729), NT-proBNP (HR 2.04 [1.90-4.55] for ≥ 337 ng/L and 1.48 [1.05-2.10] for 89-337 ng/L compared to < 89 ng/L, C-statistic = 0.741), and 15-year mortality in T2DM, whereas increased mortality was observed in patients with hs-cTnI ≥ 7.8 ng/L (HR 1.63 [1.01-2.62]). A 'cardiac score' based on the combination of sST2, hs-cTnI, and NT-proBNP was significantly associated with all-cause mortality (HR 1.35 [1.19-1.53], C-statistic = 0.739) and development of CV events. sST2, hs-cTnI, and NT-proBNP are associated with 15-year mortality and onset of CV events in T2DM. The long-term prognostic value of sST2 and its ability to track variables related to insulin resistance and associated metabolic disorders support its implementation into routine clinical practice.
Sections du résumé
BACKGROUND
Patients with type 2 diabetes (T2DM) present an increased risk of cardiovascular (CV) disease and excess CV-related mortality. Beyond the established role of brain natriuretic peptide (BNP) and cardiac troponins (cTn), other non-cardiac-specific biomarkers are emerging as predictors of CV outcomes in T2DM.
METHODS
Serum levels of soluble suppression of tumorigenesis 2 (sST2), high-sensitivity (hs)-cTnI, and N-terminal (NT)-proBNP were assessed in 568 patients with T2DM and 115 healthy controls (CTR). Their association with all-cause mortality and the development of diabetic complications was tested in T2DM patients over a median follow-up of 16.8 years using Cox models and logistic regressions.
RESULTS
sST2 followed an increasing trend from CTR to uncomplicated T2DM patients (T2DM-NC) to patients with at least one complication (T2DM-C), while hs-cTnI was significantly higher in T2DM-C compared to CTR but not to T2DM-NC. A graded association was found between sST2 (HR 2.76 [95% CI 1.20-6.33] for ≥ 32.0 ng/mL and 2.00 [1.02-3.94] for 16.5-32.0 ng/mL compared to < 16.5 ng/mL, C-statistic = 0.729), NT-proBNP (HR 2.04 [1.90-4.55] for ≥ 337 ng/L and 1.48 [1.05-2.10] for 89-337 ng/L compared to < 89 ng/L, C-statistic = 0.741), and 15-year mortality in T2DM, whereas increased mortality was observed in patients with hs-cTnI ≥ 7.8 ng/L (HR 1.63 [1.01-2.62]). A 'cardiac score' based on the combination of sST2, hs-cTnI, and NT-proBNP was significantly associated with all-cause mortality (HR 1.35 [1.19-1.53], C-statistic = 0.739) and development of CV events.
CONCLUSIONS
sST2, hs-cTnI, and NT-proBNP are associated with 15-year mortality and onset of CV events in T2DM. The long-term prognostic value of sST2 and its ability to track variables related to insulin resistance and associated metabolic disorders support its implementation into routine clinical practice.
Identifiants
pubmed: 36088327
doi: 10.1186/s12933-022-01616-3
pii: 10.1186/s12933-022-01616-3
pmc: PMC9463761
doi:
Substances chimiques
Interleukin-1 Receptor-Like 1 Protein
0
Peptide Fragments
0
Troponin I
0
Troponin T
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
180Informations de copyright
© 2022. The Author(s).
Références
Clin Chim Acta. 2020 Nov;510:150-156
pubmed: 32652160
Cardiovasc Diabetol. 2011 Nov 21;10:101
pubmed: 22104207
J Cardiovasc Med (Hagerstown). 2019 Feb;20(2):81-90
pubmed: 30540645
Am J Med. 2020 Jan;133(1):115-122.e2
pubmed: 31247182
J Am Soc Nephrol. 2015 Apr;26(4):946-56
pubmed: 25278510
Geroscience. 2021 Apr;43(2):985-1001
pubmed: 33131010
Medicine (Baltimore). 2015 Nov;94(47):e1889
pubmed: 26632683
Clin Chem Lab Med. 2016 Jan;54(1):29-35
pubmed: 26544104
Stat Med. 2011 Jan 15;30(1):11-21
pubmed: 21204120
Kidney Int Rep. 2018 Sep 21;4(1):103-111
pubmed: 30596173
J Clin Med. 2020 Feb 18;9(2):
pubmed: 32085400
Diabetes Care. 2014;37(1):295-303
pubmed: 24089534
Diabetes Care. 2020 Dec;43(12):2930-2937
pubmed: 32816995
Circulation. 2022 Jan 18;145(3):158-169
pubmed: 34743554
J Am Coll Cardiol. 2018 Nov 6;72(19):2309-2320
pubmed: 30384887
Diabetes Care. 2020 Oct;43(10):e144-e146
pubmed: 32788284
ESC Heart Fail. 2020 Aug;7(4):1488-1501
pubmed: 32424982
Cardiovasc Diabetol. 2019 May 28;18(1):64
pubmed: 31138195
Am J Cardiol. 2015 Apr 2;115(7 Suppl):22B-5B
pubmed: 25665763
Future Cardiol. 2014 Jul;10(4):525-39
pubmed: 25301315
J Am Heart Assoc. 2019 Nov 5;8(21):e012336
pubmed: 31645163
J Am Coll Cardiol. 2017 May 30;69(21):2646-2656
pubmed: 28545639
JAMA Cardiol. 2016 Dec 01;1(9):989-998
pubmed: 27681000
J Am Heart Assoc. 2016 May 31;5(6):
pubmed: 27247335
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
J Am Coll Cardiol. 2019 Oct 29;74(17):2193-2203
pubmed: 31648713
Circulation. 2015 Dec 15;132(24):2297-304
pubmed: 26518765
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Nat Rev Drug Discov. 2008 Oct;7(10):827-40
pubmed: 18827826
Comput Methods Programs Biomed. 2019 Aug;177:133-139
pubmed: 31319941
Diabetes Metab Syndr Obes. 2020 Aug 03;13:2711-2718
pubmed: 32801817
Clin Chim Acta. 2019 Sep;496:25-34
pubmed: 31201817
J Am Heart Assoc. 2020 Oct 20;9(19):e017462
pubmed: 32964800
Circ Res. 2016 May 27;118(11):1723-35
pubmed: 27230638
Clin Chem. 2021 Jan 8;67(1):96-106
pubmed: 33225348
Oncotarget. 2016 Aug 9;7(32):50835-50844
pubmed: 27437767
Hypertension. 2018 Oct;72(4):818-828
pubmed: 30354724
Acta Diabetol. 2019 Mar;56(3):273-280
pubmed: 30259114
Diabetes. 2020 Apr;69(4):713-723
pubmed: 31974140
Cell Mol Immunol. 2017 Feb;14(2):143-145
pubmed: 28017959
Diabetologia. 2018 May;61(5):987-995
pubmed: 28956084
Circ Heart Fail. 2016 Sep;9(9):
pubmed: 27582282
Clin Biochem. 2017 Oct;50(15):813-815
pubmed: 28392226
J Card Fail. 2013 Nov;19(11):768-75
pubmed: 24263122
Cardiovasc Diabetol. 2021 Feb 19;20(1):49
pubmed: 33608010
Circ Res. 2018 Aug 17;123(5):614-629
pubmed: 30355136
Diabetes Care. 2016 May;39(5):677-85
pubmed: 26740635
Diabetologia. 2015 Jun;58(6):1363-71
pubmed: 25740695
Cardiovasc Diabetol. 2022 Jun 6;21(1):95
pubmed: 35668468
Diabetes Care. 2018 Jul;41(7):1510-1515
pubmed: 29848776